- PepGen to Participate in Upcoming Investor Conferences
- PepGen Receives U.S. FDA Orphan Drug and Rare Pediatric Disease Designations for PGN-EDO51 for the Treatment of Duchenne Muscular Dystrophy
- PepGen Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Corporate Developments
- PepGen Announces Clearance of CTA by UK Medicines & Healthcare Products Regulatory Agency to Begin CONNECT2-EDO51, a Phase 2 Clinical Trial designed to support potential accelerated approval of PGN-EDO51 for the Treatment of Duchenne Muscular Dystrophy
- PepGen Receives U.S. FDA Fast Track Designation for PGN-EDODM1 for the Treatment of Myotonic Dystrophy Type 1
- PepGen Announces Pricing of $80.1 Million Underwritten Offering of Common Stock
- Mary Beth DeLena Joins PepGen as General Counsel and Secretary
- PepGen Announces First Patient Dosed in CONNECT1-EDO51 Phase 2 Clinical Trial of PGN-EDO51 for Duchenne Muscular Dystrophy Patients Amenable to Exon 51 Skipping
- PepGen Announces First Patient Dosed in Phase 1 FREEDOM-DM1 Clinical Trial of PGN-EDODM1 for Myotonic Dystrophy Type 1 (DM1)
- PepGen Announces Appointment of Howard Mayer, M.D. to Board of Directors
More ▼
Key statistics
As of last trade PepGen Inc (PEPG:NSQ) traded at 14.78, -15.59% below its 52-week high of 17.51, set on Mar 05, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 14.20 |
---|---|
High | 14.90 |
Low | 14.03 |
Bid | 14.66 |
Offer | 14.90 |
Previous close | 14.09 |
Average volume | 122.80k |
---|---|
Shares outstanding | 32.35m |
Free float | 23.80m |
P/E (TTM) | -- |
Market cap | 455.87m USD |
EPS (TTM) | -3.30 USD |
Data delayed at least 15 minutes, as of Mar 28 2024 17:59 BST.
More ▼